Cogentix Medical 10-Q 14 Aug 14 2014 Q1 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	3 Months Ended
	Jun. 30, 2014	Aug. 13, 2014
Document and Entity Information [Abstract]	'	'
Entity Registrant Name	'VISION SCIENCES INC /DE/	'
Document Type	'10-Q	'
Current Fiscal Year End Date	'--03-31	'
Entity Common Stock, Shares Outstanding	'	47,620,451
Amendment Flag	'false	'
Entity Central Index Key	'0000894237	'
Entity Current Reporting Status	'Yes	'
Entity Voluntary Filers	'No	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Well-known Seasoned Issuer	'No	'
Document Period End Date	30-Jun-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q1	'

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations (Unaudited) (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013
Net sales	$3,752	$3,652
Cost of sales	2,603	2,572
Gross profit	1,149	1,080
Selling, general, and administrative expenses	2,491	3,050
Research and development expenses	536	419
Operating loss	-1,878	-2,389
Interest expense	-83	-41
Other, net	-16	-4
Loss before provision for income taxes	-1,977	-2,434
Net loss per common share - basic and diluted (in Dollars per share)	($0.04)	($0.05)
Weighted average shares used in computing net loss per common share - basic and diluted (in Shares)	46,260	46,109
Net loss	($1,977)	($2,434)

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) (USD $)	Jun. 30, 2014	Mar. 31, 2014
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$1,270	$1,237
Accounts receivable, less allowances of $174 and $117, respectively	3,316	3,818
Inventories, net	4,192	4,194
Prepaid expenses and other current assets	438	455
Total current assets	9,216	9,704
Machinery and equipment	3,467	3,456
Demo equipment	1,456	1,311
Furniture and fixtures	237	225
Leasehold improvements	372	372
Property and equipment, at cost	5,532	5,364
Less—accumulated depreciation and amortization	-4,437	-4,302
Total property and equipment, net	1,095	1,062
Other assets, net	67	67
Total assets	10,378	10,833
Current liabilities:	'	'
Accounts payable	1,145	1,217
Accrued expenses	921	918
Accrued compensation	679	474
Deferred revenue	303	210
Capital lease obligations	9	22
Total current liabilities	3,057	2,841
Convertible debt—related party	23,440	22,414
Deferred revenue, net of current portion	203	93
Total liabilities	26,700	25,348
Commitments and Contingencies	'	'
Preferred stock, $0.01 par value	'	'
Authorized—5,000 shares; issued and outstanding - none	'	'
Common stock, $0.01 par value	'	'
Authorized—75,000 shares; issued and outstanding—47,620 shares and 47,614 shares, respectively	476	476
Additional paid-in capital	102,806	102,629
Treasury stock at cost, 65 and 59 shares of common stock, respectively	-85	-78
Accumulated deficit	-119,519	-117,542
Total stockholders’ deficit	-16,322	-14,515
Total liabilities and stockholders’ deficit	$10,378	$10,833

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) (USD $)	Jun. 30, 2014	Mar. 31, 2014
In Thousands, except Per Share data, unless otherwise specified
Accounts receivable, allowances (in Dollars)	$174	$117
Preferred Stock Par Value (in Dollars per share)	$0.01	$0.01
Preferred Stock, Authorized Shares	5,000	5,000
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0
Common Stock, Par Value (in Dollars per share)	$0.01	$0.01
Common Stock, Authorized Shares	75,000	75,000
Common Stock, Shares Issued	47,620	47,614
Common stock, Shares Outstanding	47,620	47,614
Treasury Stock, Shares	65	59

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013
Cash flows from operating activities:	'	'
Net loss	($1,977)	($2,434)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Depreciation and amortization	166	188
Stock-based compensation expense	154	555
Provision for bad debt expense	44	8
Amortization of debt discount	26	'
Loss on disposal of fixed assets	6	3
Changes in assets and liabilities:	'	'
Accounts receivable	458	931
Inventories	-178	-191
Prepaid expenses and other current assets	17	-85
Accounts payable	-72	-483
Accrued expenses	3	-133
Accrued compensation	205	210
Deferred revenue	203	12
Net cash used in operating activities	-945	-1,419
Cash flows from investing activities:	'	'
Purchases of property and equipment	-25	'
Net cash used in investing activities	-25	'
Cash flows from financing activities:	'	'
Proceeds from issuance of convertible debt-related party	1,000	2,000
Proceeds from exercise of stock options	23	'
Common stock repurchased	-7	-18
Payments of capital leases	-13	-19
Net cash provided by financing activities	1,003	1,963
Net increase in cash and cash equivalents	33	544
Cash and cash equivalents at beginning of period	1,237	788
Cash and cash equivalents at end of period	1,270	1,332
Non-cash financing activities:	'	'
Net transfers of inventory to fixed assets for use as demonstration equipment	$180	$116

Note_1_Summary_of_Significant_

Note 1 - Summary of Significant Accounting Policies	3 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
Significant Accounting Policies [Text Block]	'
	Note 1.   Summary of Significant Accounting Policies
	Vision-Sciences, Inc. and its subsidiaries (the “Company,” or “our”, “us” or “we”) designs, develops, manufactures, and markets products for endoscopy – the science of using an instrument, known as an endoscope, to provide minimally invasive access to areas not readily visible to the human eye. Our products are sold throughout the world through direct sales representatives in the United States (“U.S.”) and independent distributors for the rest of the world. We are the exclusive supplier of ureteroscopes to the Endoscopy Division of Stryker Corporation (“Stryker”). Our largest geographic markets are the U.S. and Europe.
	We are incorporated in Delaware, and are the successor to operations begun in 1987. In December 1990, Machida Incorporated (“Machida”) became our wholly-owned subsidiary. We own the registered trademarks Vision Sciences®, EndoSheath®, EndoWipe®, Slide-On® and The Vision System®. Not all products referenced in this report are approved or cleared for sale, distribution, or use.
	Basis of Presentation and Preparation
	We have prepared the condensed consolidated financial statements included herein according to generally accepted accounting principles in the United States of America (“U.S. GAAP”), without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and include, in the opinion of management, all adjustments that we consider necessary for a fair presentation of such information.  We have condensed or omitted certain information and footnote disclosures normally included in financial statements pursuant to those rules and regulations. We believe, however, that our disclosures are adequate to make the information presented not misleading.
	The results for the interim periods presented are not necessarily indicative of results to be expected for the full fiscal year. Please read these condensed consolidated financial statements in conjunction with the consolidated financial statements and the related notes included in our Annual Report on Form 10-K for the fiscal year ended March 31, 2014.
	Liquidity and Capital Resources
	We have incurred substantial operating losses since our inception and there can be no assurance that we will ever achieve or sustain a profitable level of operations in the future. We anticipate that we will continue to incur negative cash flows from operations during the remainder of fiscal 2015, driven by continued investment in a direct sales force for the U.S. market, spending for marketing, revitalizing a research and development pipeline, and general business operations. As of June 30, 2014, we had cash and cash equivalents totaling approximately $1.3 million. On June 16, 2014, we issued a convertible promissory note to Lewis C. Pell, our Chairman that allowed us to borrow up to $5.0 million, or the 2014 Note. The 2014 Note was issued in accordance with a letter agreement dated May 29, 2014 from Mr. Pell that provided for up to $5.0 million of capital to be made available to us, subject to certain conditions and an expiration date of July 1, 2015. The letter agreement was then terminated. As of June 30, 2014, we had $1.0 million in principal outstanding under the 2014 Note. We expect that our cash at June 30, 2014, together with $4.0 million remaining to be drawn under the 2014 Note, should be sufficient to fund our operations through at least June 30, 2015. However, if our performance expectations fall short (including our failure to generate expected levels of sales) or our expenses exceed expectations, or if the commitment under the 2014 Note becomes unavailable, we will need to secure additional financing and/or reduce our expenses to continue our operations. Our failure to do so would have a material adverse impact on our prospects and financial condition. There can be no assurance that any contemplated additional financing will be available on terms acceptable to us, if at all. If required, we believe we would be able to reduce our expenses to a sufficient level to continue to operate as a going concern.
	Summary of Significant Accounting Policies
	Our condensed consolidated financial statements are prepared in accordance with the rules and regulations of the SEC for interim reporting and U.S. GAAP. These accounting principles require us to make certain estimates, judgments and assumptions. We believe that the estimates, judgments and assumptions upon which we rely are reasonable, based upon information available to us at the time that these estimates, judgments and assumptions are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities as of the date of the financial statements as well as the reported amounts of revenues and expenses during the periods presented. To the extent there are any differences (other than nominal differences) between these estimates, judgments or assumptions and actual results, our financial statements will be affected.
	In the opinion of our Company’s management, the accompanying unaudited condensed financial statements contain all adjustments(consisting of normal recurring adjustments) necessary to present fairly, in all material respects, our financial position as of June 30, 2014 and the results of operations and cash flows for the three months then ended. The results of operations and cash flows for the period ended June 30, 2014 are not necessarily indicative of the results of operations or cash flows to be expected for any subsequent quarter or the full fiscal year ending March 31, 2015. As of June 30, 2014, there have been no material changes to any of the significant accounting policies described in our Report on Form 10-K for the year ended March 30, 2014.
	The accompanying condensed consolidated financial statements reflect the accounts of the Company. All significant inter-company accounts and transactions have been eliminated in consolidation.
	New Accounting Pronouncement
	In May 2014, the Financial Accounting Standards Board (FASB) issued new accounting guidance, namely (“ASU”) No. 2014-09, Revenue from Contracts with Customers, on revenue recognition. The new standard provides for a single five-step model to be applied to all revenue contracts with customers as well as requires additional financial statement disclosures that will enable users to understand the nature, amount, timing and uncertainty of revenue and cash flows relating to customer contracts. Companies have an option to use either a retrospective approach or cumulative effect adjustment approach to implement the standard. There is no option for early adoption. For public entities, this ASU is effective for fiscal years and interim periods within those years beginning after December 15, 2016. We are currently evaluating the impact of the new guidance on our consolidated financial statements.
	Fair Value Measurements
	The carrying amounts reflected in our condensed consolidated balance sheets for cash and cash equivalents, accounts receivable, other current assets, accounts payable, accrued expenses, accrued compensation, and capital lease obligations approximate fair value due to their short-term nature. The carrying value of our convertible debt-related party approximates fair value due to its attributes, which include, amongst others, interest and its conversion feature into common stock.
	In determining the fair value of the convertible debt – related party, we analyzed its attributes (coupon rate, conversion price, and the percentage of market cap the face value of the debt instrument was prior to the announcement of the debt) as compared to public company convertible debt issuances in the healthcare industry. We determined the convertible debt was not issued at a discount as its fair value was equal to its face (carrying) value.
	Concentration of Credit Risk
	Concentration of credit risk with respect to accounts receivables relates to certain domestic and international customers to whom we make substantial sales. To reduce risk, we routinely assess the financial strength of our customers and, when appropriate, we obtain advance payments for our international sales. As a consequence, we believe that our accounts receivable credit risk exposure is limited. We maintain an allowance for potential credit losses, but historically we have not experienced any significant credit losses related to any individual customer or group of customers in any particular industry or geographic area.
	The following table summarizes net sales to our significant customers which accounted for more than 10% of total segment net sales and total accounts receivable, net:
		June 30,			June 30,
		2014			2013
	Medical segment
	Stryker	$	478		$	1,144
	Percentage of total segment net sales for the three months ended		16	%		38	%
	Percentage of total net sales for the three months ended		13	%		31	%
	Percentage of total accounts receivable, net as of		14	%		26	%

Note_2_Basic_and_Diluted_Net_L

Note 2 - Basic and Diluted Net Loss per Common Share	3 Months Ended
	Jun. 30, 2014
Earnings Per Share [Abstract]	'
Earnings Per Share [Text Block]	'
	Note 2.   Basic and Diluted Net Loss per Common Share
	Basic net loss per common share is calculated by dividing the net loss by the weighted average number of common shares outstanding. For all periods presented, the diluted net loss per common share is the same as basic net loss per common share, as the inclusion of other shares of stock issuable pursuant to convertible debt, stock options and warrants would be anti-dilutive. The following table summarizes equity securities that were excluded from the calculation of fully diluted net loss per share as of June 30, 2014 and 2013, respectively:
		June 30,
		2014		2013
	Convertible debt		21,500,150		15,833,333
	Stock options		4,346,369		6,076,858
	Warrants		1,880,620		1,880,620
	Restricted stock		1,236,647		78,028
	Total anti-dilutive securities		28,963,786		23,868,839

Note_3_Inventories

Note 3 - Inventories	3 Months Ended
	Jun. 30, 2014
Inventory Disclosure [Abstract]	'
Inventory Disclosure [Text Block]	'
	Note 3.   Inventories
	Inventories are stated at the lower of cost or market using the first-in, first-out (“FIFO”) method and consist of the following:
		June 30,		March 31,
		2014		2014
	Raw materials	$	3,482	$	3,456
	Work in process		318		329
	Finished goods		392		409
	Inventories, net	$	4,192	$	4,194
	Raw materials include components purchased from independent suppliers. Most purchased components are available from multiple sources, with the exception of certain key components that are supplied to us by suppliers with whom we have long-term supply arrangements, but no long-term supply agreements.

Note_4_Supply_Agreements

Note 4 - Supply Agreements	3 Months Ended
	Jun. 30, 2014
Deferred Revenue Disclosure [Abstract]	'
Deferred Revenue Disclosure [Text Block]	'
	Note 4.   Supply Agreements
	We are the exclusive supplier of the following Stryker-branded flexible endoscopes:
	Market	Product	Term
	Urology	URT-7000 Video Ureteroscope	3- year agreement (December 2012-December 2015)
		Peripherals and accessories (ureteroscopy)	3- year agreement (December 2012-December 2015)
	Stryker has the exclusive rights to distribute our ureteroscope in the United States.
	From April 2011 through May 2014, Stryker had the rights to market and sell our cystoscopes, the CST- 5000 Video Cystoscope and the CST-4000 Fiber Cystoscope, and the accompanying EndoSheath disposables, peripherals and accessories. We decided to not renew this exclusivity and to directly sell the cystoscopes, their EndoSheaths, peripherals and accessories in the U.S. We made this decision in large part because Stryker’s endoscopy sales force focuses on the operating room in hospitals, while most cystoscopy procedures are performed in physicians’ offices and ambulatory surgical centers.

Note_5_Convetible_Debt_Related

Note 5 - Convetible Debt - Related Party	3 Months Ended
	Jun. 30, 2014
Related Party Transactions [Abstract]	'
Related Party Transactions Disclosure [Text Block]	'
	Note 5.   Convertible debt – related party
	Convertible Promissory Note:
	The following table is a summary of our convertible debt – related party at June 30, 2014:
	Convertible debt – related party	Gross			Unamortized			Net Amount
		Principal			Debt Discount			Outstanding
		Amount
		Outstanding
	Replacement Note	$	20,000		$	-		$	20,000
	2013 Note		3,500			(1,060	)		2,440
	2014 Note		1,000			-			1,000
		$	24,500		$	1,060		$	23,440
	Pursuant to a May 29, 2014 Letter Agreement between us and Mr. Lewis C. Pell, or the Letter Agreement, Mr. Pell agreed to provide financial assistance to us in the amount of up to $5.0 million, if necessary to support our operations, for a period ending on the earlier of (i) July 1, 2015 or (ii) our raising debt or equity capital in the amount of $5.0 million or more. This Letter Agreement provided that this financial assistance, if drawn by us, would be in the form of an additional loan, share purchase, or financing transaction, on such terms as we and Mr. Pell may determine. The Letter Agreement was terminated upon the issuance of the 2014 Note.
	Pursuant to the Letter Agreement, on June 16, 2014, or the 2014 Effective Date, we entered into the 2014 Note with Mr. Pell that allowed us to borrow up to $5.0 million. The 2014 Note accrues annual interest at the rate of 1.91%. The 2014 Note must be repaid in full on or before the fifth anniversary of the 2014 Effective Date, or the 2014 Maturity Date, but may be prepaid by us at any time without penalty. We will be required to repay all amounts outstanding under the 2014 Note upon an event of default, as defined in the 2014 Note. The outstanding principal amount of the 2014 Note is convertible at any time prior to the 2014 Maturity Date, at Mr. Pell’s option, into shares of our common stock at a price of $1.11, the closing bid price of our common stock on the 2014 Effective Date. At June 30, 2014, we had outstanding principal borrowings of $1.0 million under the 2014 Note, which is included in convertible debt – related party on our condensed consolidated balance sheet. Each time we draw on any available credit under the 2014 Note, we determine if a beneficial conversion feature of the convertible debt exists. A beneficial conversion feature will arise if the $1.11 conversion price of the 2014 Note is below the per share fair value of our common stock on the date of a draw down.
	On September 25, 2013, or the 2013 Effective Date, we entered into a convertible promissory note, or the 2013 Note with Mr. Pell that allowed us to borrow up to $3.5 million. The 2013 Note accrues annual interest, at the rate of 1.66%. The 2013 Note must be repaid in full on or before the fifth anniversary of the 2013 Effective Date, or the 2013 Maturity Date, but may be prepaid by us at any time without penalty. We will be required to repay all amounts outstanding under the 2013 Note upon an event of default, as defined in the 2013 Note. The outstanding principal amount of the 2013 Note is convertible at any time prior to the 2013 Maturity Date, at Mr. Pell’s option, into shares of our common stock at a price of $0.89, the closing bid price of our common stock on the 2013 Effective Date. At June 30, 2014, we had outstanding principal borrowings of $3.5 million, gross of the amount recognized as a beneficial conversion feature, under the 2013 Note, which is included in convertible debt – related party on our consolidated balance sheet.
	During each draw upon the 2013 Note, a beneficial conversion feature was recorded as a result of the market price of our common stock increasing after the 2013 Effective Date. The following table summarizes the beneficial conversion feature amounts recorded as of June 30, 2014:
	Date	Borrowing Amount			Convertible Shares			Share Price on Borrowing Date		Gross Beneficial Conversion Feature
	7-Oct-13	$	1,000			1,123,595		$	0.95	$	67
	26-Nov-13	$	1,000			1,123,595			1.01		135
	21-Jan-14	$	1,000			1,123,595			1.39		562
	13-Mar-14	$	500			561,799			1.54		365
		$	3,500			3,932,584				$	1,129
	The beneficial conversion feature amounts were recorded as a convertible debt discount with a corresponding increase to additional paid-in capital. The amounts are being amortized using the effective interest rate method over a five-year period from the borrowing date to the Maturity Date. At June 30, 2014, the unamortized convertible debt discount balance was $1.1 million and is expected to be recognized over a period of approximately 4.2 years.
	On September 19, 2012, or the Replacement Note Effective Date, we entered into a convertible promissory note or the Replacement Note with Mr. Pell that allowed us to borrow up to $20.0 million. The Replacement Note (i) consolidated and restructured the $15.0 million in aggregate borrowings collectively outstanding under an Amended and Restated Loan Agreement, dated September 30, 2011, between us and Mr. Pell, or the Original Agreement and a separate promissory note, dated July 25, 2012, between us and Mr. Pell, and (ii) provided for up to $5.0 million in additional borrowings.
	The Replacement Note accrues annual interest, payable annually, at the rate of 0.84%. The Replacement Note must be repaid in full on or before the fifth anniversary of the Replacement Note Effective Date, or the Replacement Note Maturity Date, but may be prepaid by us at any time without penalty. We will be required to repay all amounts outstanding under the Replacement Note upon an event of default, as defined in the Replacement Note.
	The outstanding principal amount of the Replacement Note is convertible at any time prior to the Replacement Note Maturity Date, at Mr. Pell’s option, into shares of our common stock at a conversion price of $1.20 per share, which was the closing bid price of our common stock on the Replacement Note Effective Date. At June 30, 2014, we had $20.0 million in outstanding principal borrowings under the Replacement Note, which is reflected as convertible debt – related party on our consolidated balance sheet.
	Pursuant to the Original Agreement, Mr. Pell received warrants to purchase an aggregate of 1,880,620 shares of our common stock at a weighted average exercise price of $1.86 per share. All of the warrants are vested and expire on the later of September 30, 2016 or one year after the termination of the Original Agreement and repayment of all amounts due and payable under the Original Agreement.
	Amortization of the convertible debt discount and interest expense related to the accrued interest on outstanding borrowings are recorded as interest expense in our condensed consolidated statement of operations. Interest expense for the three months ended June 30, 2014 and 2013, respectively, was comprised of:
		Three months
		ended June 30,
		2014			2013
	Amortization of convertible debt discount	$	(26	)	$	-
	Interest Expense		(57	)		(41	)
		$	(83	)	$	(41	)
	At June 30, 2014, we had an aggregate amount of $311 thousand in accrued interest under the 2014 Note, the 2013 Note and the Replacement Note, which is included in accrued expenses on our condensed consolidated balance sheet.

Note_6_StockBased_Awards

Note 6 - Stock-Based Awards	3 Months Ended
	Jun. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	'
	Note 6.  Stock-Based Awards
	We maintain the following stockholder-approved equity incentive plans:
		●	The 2000 Stock Incentive Plan (the “2000 Plan”) authorizes the issuance of up to 4,500,000 shares of common stock covering several different types of awards, including stock options, restricted shares, stock appreciation rights, and performance shares.
		●	The 2007 Stock Incentive Plan, as amended, (the “2007 Plan) authorizes the issuance of up to 7,000,000 shares of common stock covering several different types of awards, including stock options, restricted shares, stock appreciation rights, and other stock-based awards.
		●	The 2003 Director Option Plan (the “2003 Plan”) authorizes the issuance of up to 450,000 shares of common stock covering the annual automatic grant, unless waived, of 10,000 stock options per outside director per year. The 2003 Plan also provides for granting newly elected or appointed outside directors a one-time grant of 10,000 stock options.
	The stock option plans provide that options may be granted at an exercise price of 100% of fair market value of our common stock on the date of grant, may be exercised in full or in installments, at the discretion of our Board of Directors (the “Board”) or its Compensation Committee (the “Compensation Committee”), and must be exercised within ten years from date of grant. We recognize stock-based compensation expense on a straight-line basis over the requisite service period based on fair values, generally four years. We use historical data to estimate expected employee behaviors related to option exercises and forfeitures and included these expected forfeitures as a part of the estimate of stock-based compensation expense as of the grant date.
	Stock Options
	The following table summarizes stock options activity for the three months ended June 30, 2014:
			Number			Exercise						Weighted		Weighted
			of Shares			Price Range						Average		Average
												Exercise Price		Remaining
														Contractual Life
	Outstanding at April 1, 2014			4,377,874			$0.85		–	$	4.88	$	1.78		6
	Granted			430,000			$1.04		–	$	1.25		1.12
	Exercised			(25,000	)		$0.97		–	$	0.97		0.97
	Canceled			(426,505	)		$0.95		–	$	4.3		2.65
	Outstanding at June 30, 2014			4,356,369			$0.85		–	$	4.88	$	1.64		5.8
	Vested and expected to vest at June 30, 2014			4,310,973			$0.85		–	$	4.88	$	1.64		5.8
	Exercisable at June 30, 2014			3,558,703			$0.85		–	$	4.88	$	1.73		5
	The weighted average fair value of options granted during the three months ended June 30, 2014 and 2013 was $0.77 and $0.70 per share, respectively.
	The total intrinsic value (the excess of the market price over the exercise price) was approximately $234 thousand for stock options outstanding, $180 thousand for stock options exercisable, and $230 thousand for stock options vested and expected to vest as of June 30, 2014.
	We do not expect to realize any tax benefits from future disqualifying dispositions, if any.
	Restricted Stock
	We determine stock-based compensation expense for performance based restricted stock based upon the fair value of our common stock at the date of grant and recognize expense based upon the most probable outcome as to whether the performance targets will be achieved and the stock-based compensation being earned.
	The following table summarizes restricted stock activity for the three months ended June 30, 2014:
			Number			Weighted
			of Shares			Average
						Grant Price
	Nonvested at April 1, 2014			1,325,402		$	1.06
	Vested			(68,950	)		1.51
	Forfeited			(19,805	)		1.62
	Nonvested at June 30, 2014			1,236,647		$	1.05
	We grant restricted stock awards to certain executive officers and management employees and certain members of our Board.
	Stock-Based Compensation Expense
	We estimated the fair value of the stock options granted on the date of grant using a Black-Scholes valuation model that used the weighted average assumptions noted in the following table. The risk-free interest rate assumption we use is based upon United States Treasury interest rates appropriate for the expected life of the awards. The expected life (estimated period of time that we expect employees, consultants and directors to hold their stock options) was estimated based on historical rates for two group classifications, (i) employees and consultants and (ii) outside directors. Expected volatility was based on historical volatility of our stock price for a period equal to the stock option’s expected life and calculated on a daily basis. The expected dividend rate is zero since we do not currently pay cash dividends on our common stock and do not anticipate doing so in the foreseeable future.
			Three Months Ended
			June 30,
			2014			2013
	Risk-free interest rate			1.9	%		1.3	%
	Expected life (in years)			6.7			7
	Expected volatility			77	%		82	%
	Expected dividend yield			--			--
	The following table summarizes stock-based compensation recorded in our consolidated statements of operations for the three months ended June 30, 2014 and 2013, respectively:
			Three Months Ended
			June 30,
			2014			2013
	Cost of sales		$	16		$	30
	Selling, general, and administrative expenses			123			509
	Research and development expenses			15			16
	Total stock-based compensation expense		$	154		$	555
	At June 30, 2014, unrecognized stock-based compensation expense related to stock options was approximately $0.6 million and is expected to be recognized over a weighted average period of approximately 3.1 years. At June 30, 2014, unrecognized stock-based compensation expense related to nonvested (restricted stock) awards was approximately $0.4 million, which is expected to be recognized over a weighted average period of approximately 3.4 years.

Note_7_Treasury_Stock

Note 7 - Treasury Stock	3 Months Ended
	Jun. 30, 2014
Disclosure Text Block Supplement [Abstract]	'
Treasury Stock [Text Block]	'
	Note 7. Treasury Stock
	The following table summarizes treasury stock activity for the three months ended June 30, 2014 and 2013, respectively:
	Three Months Ended	Number		Cost		Weighted
		of Shares				Average
		Repurchased				Purchase Price
	30-Jun-14		5	$	6	$	1.22
	30-Jun-13		15	$	18	$	1.14
	The shares were purchased from management employees to cover income tax withholdings upon the lapse of restrictions on their restricted stock awards.

Note_8_Segment_Information

Note 8 - Segment Information	3 Months Ended
	Jun. 30, 2014
Segment Reporting [Abstract]	'
Segment Reporting Disclosure [Text Block]	'
	Note 8.  Segment Information
	We have two reportable segments, medical and industrial. Each of these operating segments has unique characteristics. Management evaluates the revenue and profitability performance of each of our product lines to make operating and strategic decisions. We have no intersegment revenue.
	Our medical segment designs, manufactures and sells our advanced line of endoscopy-based products, including our state-of-the-art flexible endoscopes, and our EndoSheath technology (referred to as a sheath or EndoSheath disposable) for a variety of specialties and markets.
	Our industrial segment, through our wholly-owned subsidiary Machida, designs, manufactures, and sells borescopes to a variety of users, primarily in the aircraft engine manufacturing and aircraft engine maintenance industries. A borescope is an instrument that uses optical fibers for the visual inspection of narrow cavities. Our borescopes are used to inspect aircraft engines, casting parts and ground turbines, among other items.
	The following table presents key financial highlights by reportable segments:
	Three Months Ended June 30, 2014	Medical			Industrial				Adjustments*		Consolidated
	Net sales	$	3,060		$	692		$	-		$	3,752
	Gross profit		897			252			-			1,149
	Operating loss		(1,838	)		(40	)		-			(1,878	)
	Interest expense, net		83			-			-			83
	Depreciation and amortization		164			2			-			166
	Stock-based compensation expense		142			12			-			154
	As of June 30, 2014
	Total assets		10,868			1,640			(2,130	)		10,378
	Expenditures for fixed assets		25			-			-			25
	Three Months Ended June 30, 2013
	Net sales	$	3,029		$	623		$	-		$	3,652
	Gross profit		793			287			-			1,080
	Operating loss		(2,387	)		(2	)		-			(2,389	)
	Interest expense, net		41			-			-			41
	Depreciation and amortization		184			4			-			188
	Stock-based compensation expense		531			24			-			555
	As of June 30, 2013
	Total assets		11,615			1,679			(2,224	)		11,070
	Expenditures for fixed assets		-			-			-			-
		Three months ended
		June 30,
	* Adjustments	2014			2013
	Intercompany eliminations	$	(1,444	)	$	(1,538	)
	Investment in subsidiaries		(686	)		(686	)
	Total adjustments	$	(2,130	)	$	(2,224	)

Note_9_Subsequent_Event

Note 9 - Subsequent Event	3 Months Ended
	Jun. 30, 2014
Subsequent Events [Abstract]	'
Subsequent Events [Text Block]	'
	Note 9. Subsequent Event
	On August 13, 2014, we drew down another $1.0 million under the 2014 Note. As of the date hereof, we had $2.0 million in principal outstanding under the 2014 Note.

Accounting_Policies_by_Policy_

Accounting Policies, by Policy (Policies)	3 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
Basis of Accounting, Policy [Policy Text Block]	'
	Basis of Presentation and Preparation
	We have prepared the condensed consolidated financial statements included herein according to generally accepted accounting principles in the United States of America (“U.S. GAAP”), without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and include, in the opinion of management, all adjustments that we consider necessary for a fair presentation of such information.  We have condensed or omitted certain information and footnote disclosures normally included in financial statements pursuant to those rules and regulations. We believe, however, that our disclosures are adequate to make the information presented not misleading.
	The results for the interim periods presented are not necessarily indicative of results to be expected for the full fiscal year. Please read these condensed consolidated financial statements in conjunction with the consolidated financial statements and the related notes included in our Annual Report on Form 10-K for the fiscal year ended March 31, 2014.
Liquidity Disclosure [Policy Text Block]	'
	Liquidity and Capital Resources
	We have incurred substantial operating losses since our inception and there can be no assurance that we will ever achieve or sustain a profitable level of operations in the future. We anticipate that we will continue to incur negative cash flows from operations during the remainder of fiscal 2015, driven by continued investment in a direct sales force for the U.S. market, spending for marketing, revitalizing a research and development pipeline, and general business operations. As of June 30, 2014, we had cash and cash equivalents totaling approximately $1.3 million. On June 16, 2014, we issued a convertible promissory note to Lewis C. Pell, our Chairman that allowed us to borrow up to $5.0 million, or the 2014 Note. The 2014 Note was issued in accordance with a letter agreement dated May 29, 2014 from Mr. Pell that provided for up to $5.0 million of capital to be made available to us, subject to certain conditions and an expiration date of July 1, 2015. The letter agreement was then terminated. As of June 30, 2014, we had $1.0 million in principal outstanding under the 2014 Note. We expect that our cash at June 30, 2014, together with $4.0 million remaining to be drawn under the 2014 Note, should be sufficient to fund our operations through at least June 30, 2015. However, if our performance expectations fall short (including our failure to generate expected levels of sales) or our expenses exceed expectations, or if the commitment under the 2014 Note becomes unavailable, we will need to secure additional financing and/or reduce our expenses to continue our operations. Our failure to do so would have a material adverse impact on our prospects and financial condition. There can be no assurance that any contemplated additional financing will be available on terms acceptable to us, if at all. If required, we believe we would be able to reduce our expenses to a sufficient level to continue to operate as a going concern.
New Accounting Pronouncements, Policy [Policy Text Block]	'
	New Accounting Pronouncement
	In May 2014, the Financial Accounting Standards Board (FASB) issued new accounting guidance, namely (“ASU”) No. 2014-09, Revenue from Contracts with Customers, on revenue recognition. The new standard provides for a single five-step model to be applied to all revenue contracts with customers as well as requires additional financial statement disclosures that will enable users to understand the nature, amount, timing and uncertainty of revenue and cash flows relating to customer contracts. Companies have an option to use either a retrospective approach or cumulative effect adjustment approach to implement the standard. There is no option for early adoption. For public entities, this ASU is effective for fiscal years and interim periods within those years beginning after December 15, 2016. We are currently evaluating the impact of the new guidance on our consolidated financial statements.
Fair Value Measurement, Policy [Policy Text Block]	'
	Fair Value Measurements
	The carrying amounts reflected in our condensed consolidated balance sheets for cash and cash equivalents, accounts receivable, other current assets, accounts payable, accrued expenses, accrued compensation, and capital lease obligations approximate fair value due to their short-term nature. The carrying value of our convertible debt-related party approximates fair value due to its attributes, which include, amongst others, interest and its conversion feature into common stock.
	In determining the fair value of the convertible debt – related party, we analyzed its attributes (coupon rate, conversion price, and the percentage of market cap the face value of the debt instrument was prior to the announcement of the debt) as compared to public company convertible debt issuances in the healthcare industry. We determined the convertible debt was not issued at a discount as its fair value was equal to its face (carrying) value.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	'
	Concentration of Credit Risk
	Concentration of credit risk with respect to accounts receivables relates to certain domestic and international customers to whom we make substantial sales. To reduce risk, we routinely assess the financial strength of our customers and, when appropriate, we obtain advance payments for our international sales. As a consequence, we believe that our accounts receivable credit risk exposure is limited. We maintain an allowance for potential credit losses, but historically we have not experienced any significant credit losses related to any individual customer or group of customers in any particular industry or geographic area.
	The following table summarizes net sales to our significant customers which accounted for more than 10% of total segment net sales and total accounts receivable, net:
		June 30,			June 30,
		2014			2013
	Medical segment
	Stryker	$	478		$	1,144
	Percentage of total segment net sales for the three months ended		16	%		38	%
	Percentage of total net sales for the three months ended		13	%		31	%
	Percentage of total accounts receivable, net as of		14	%		26	%

Note_1_Summary_of_Significant_1

Note 1 - Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block]	'
		June 30,			June 30,
		2014			2013
	Medical segment
	Stryker	$	478		$	1,144
	Percentage of total segment net sales for the three months ended		16	%		38	%
	Percentage of total net sales for the three months ended		13	%		31	%
	Percentage of total accounts receivable, net as of		14	%		26	%

Note_2_Basic_and_Diluted_Net_L1

Note 2 - Basic and Diluted Net Loss per Common Share (Tables)	3 Months Ended
	Jun. 30, 2014
Earnings Per Share [Abstract]	'
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	'
		June 30,
		2014		2013
	Convertible debt		21,500,150		15,833,333
	Stock options		4,346,369		6,076,858
	Warrants		1,880,620		1,880,620
	Restricted stock		1,236,647		78,028
	Total anti-dilutive securities		28,963,786		23,868,839

Note_3_Inventories_Tables

Note 3 - Inventories (Tables)	3 Months Ended
	Jun. 30, 2014
Inventory Disclosure [Abstract]	'
Schedule of Inventory, Current [Table Text Block]	'
		June 30,		March 31,
		2014		2014
	Raw materials	$	3,482	$	3,456
	Work in process		318		329
	Finished goods		392		409
	Inventories, net	$	4,192	$	4,194

Note_5_Convetible_Debt_Related1

Note 5 - Convetible Debt - Related Party (Tables)	3 Months Ended
	Jun. 30, 2014
Related Party Transactions [Abstract]	'
Schedule of Related Party Transactions [Table Text Block]	'
	Convertible debt – related party	Gross			Unamortized			Net Amount
		Principal			Debt Discount			Outstanding
		Amount
		Outstanding
	Replacement Note	$	20,000		$	-		$	20,000
	2013 Note		3,500			(1,060	)		2,440
	2014 Note		1,000			-			1,000
		$	24,500		$	1,060		$	23,440
Convertible Debt [Table Text Block]	'
	Date	Borrowing Amount			Convertible Shares			Share Price on Borrowing Date		Gross Beneficial Conversion Feature
	7-Oct-13	$	1,000			1,123,595		$	0.95	$	67
	26-Nov-13	$	1,000			1,123,595			1.01		135
	21-Jan-14	$	1,000			1,123,595			1.39		562
	13-Mar-14	$	500			561,799			1.54		365
		$	3,500			3,932,584				$	1,129
Schedule of Other Nonoperating Income (Expense) [Table Text Block]	'
		Three months
		ended June 30,
		2014			2013
	Amortization of convertible debt discount	$	(26	)	$	-
	Interest Expense		(57	)		(41	)
		$	(83	)	$	(41	)

Note_6_StockBased_Awards_Table

Note 6 - Stock-Based Awards (Tables)	3 Months Ended
	Jun. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	'
		Number			Exercise						Weighted		Weighted
		of Shares			Price Range						Average		Average
											Exercise Price		Remaining
													Contractual Life
	Outstanding at April 1, 2014		4,377,874			$0.85		–	$	4.88	$	1.78		6
	Granted		430,000			$1.04		–	$	1.25		1.12
	Exercised		(25,000	)		$0.97		–	$	0.97		0.97
	Canceled		(426,505	)		$0.95		–	$	4.3		2.65
	Outstanding at June 30, 2014		4,356,369			$0.85		–	$	4.88	$	1.64		5.8
	Vested and expected to vest at June 30, 2014		4,310,973			$0.85		–	$	4.88	$	1.64		5.8
	Exercisable at June 30, 2014		3,558,703			$0.85		–	$	4.88	$	1.73		5
Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]	'
		Number			Weighted
		of Shares			Average
					Grant Price
	Nonvested at April 1, 2014		1,325,402		$	1.06
	Vested		(68,950	)		1.51
	Forfeited		(19,805	)		1.62
	Nonvested at June 30, 2014		1,236,647		$	1.05
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	'
		Three Months Ended
		June 30,
		2014			2013
	Risk-free interest rate		1.9	%		1.3	%
	Expected life (in years)		6.7			7
	Expected volatility		77	%		82	%
	Expected dividend yield		--			--
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	'
		Three Months Ended
		June 30,
		2014			2013
	Cost of sales	$	16		$	30
	Selling, general, and administrative expenses		123			509
	Research and development expenses		15			16
	Total stock-based compensation expense	$	154		$	555

Note_7_Treasury_Stock_Tables

Note 7 - Treasury Stock (Tables)	3 Months Ended
	Jun. 30, 2014
Disclosure Text Block Supplement [Abstract]	'
Class of Treasury Stock [Table Text Block]	'
	Three Months Ended	Number		Cost		Weighted
		of Shares				Average
		Repurchased				Purchase Price
	30-Jun-14		5	$	6	$	1.22
	30-Jun-13		15	$	18	$	1.14

Note_8_Segment_Information_Tab

Note 8 - Segment Information (Tables)	3 Months Ended
	Jun. 30, 2014
Segment Reporting [Abstract]	'
Schedule of Segment Reporting Information, by Segment [Table Text Block]	'
	Three Months Ended June 30, 2014	Medical			Industrial				Adjustments*		Consolidated
	Net sales	$	3,060		$	692		$	-		$	3,752
	Gross profit		897			252			-			1,149
	Operating loss		(1,838	)		(40	)		-			(1,878	)
	Interest expense, net		83			-			-			83
	Depreciation and amortization		164			2			-			166
	Stock-based compensation expense		142			12			-			154
	As of June 30, 2014
	Total assets		10,868			1,640			(2,130	)		10,378
	Expenditures for fixed assets		25			-			-			25
	Three Months Ended June 30, 2013
	Net sales	$	3,029		$	623		$	-		$	3,652
	Gross profit		793			287			-			1,080
	Operating loss		(2,387	)		(2	)		-			(2,389	)
	Interest expense, net		41			-			-			41
	Depreciation and amortization		184			4			-			188
	Stock-based compensation expense		531			24			-			555
	As of June 30, 2013
	Total assets		11,615			1,679			(2,224	)		11,070
	Expenditures for fixed assets		-			-			-			-
Reconciliation of Other Significant Reconciling Items from Segments to Consolidated [Table Text Block]	'
		Three months ended
		June 30,
	* Adjustments	2014			2013
	Intercompany eliminations	$	(1,444	)	$	(1,538	)
	Investment in subsidiaries		(686	)		(686	)
	Total adjustments	$	(2,130	)	$	(2,224	)

Note_1_Summary_of_Significant_2

Note 1 - Summary of Significant Accounting Policies (Details) (USD $)	Jun. 30, 2014	Mar. 31, 2014	Jun. 30, 2013	Mar. 31, 2013	Aug. 13, 2014	Jun. 30, 2014
					Board of Directors Chairman [Member]	Board of Directors Chairman [Member]
					The 2014 Note [Member]	The 2014 Note [Member]
Note 1 - Summary of Significant Accounting Policies (Details) [Line Items]	'	'	'	'	'	'
Cash and Cash Equivalents, at Carrying Value	$1,270,000	$1,237,000	$1,332,000	$788,000	'	'
Long Term Debt Maximum Amount Lender Agreed To Provide Financial Assistance	'	'	'	'	'	5,000,000
Convertible Debt, Noncurrent	23,440,000	22,414,000	'	'	2,000,000	1,000,000
Debt Instrument, Unused Borrowing Capacity, Amount	'	'	'	'	'	$4,000,000

Note_1_Summary_of_Significant_3

Note 1 - Summary of Significant Accounting Policies (Details) - Significant Customers (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013
Medical segment	'	'
Stryker (in Dollars)	$3,752	$3,652
Stryker [Member] | Medical [Member] | Sales Revenue, Segment [Member] | Customer Concentration Risk [Member]	'	'
Medical segment	'	'
Segement, concentration risk	16.00%	38.00%
Stryker [Member] | Medical [Member] | Sales Revenue, Net [Member] | Customer Concentration Risk [Member]	'	'
Medical segment	'	'
Segement, concentration risk	13.00%	31.00%
Stryker [Member] | Medical [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]	'	'
Medical segment	'	'
Segement, concentration risk	14.00%	26.00%
Stryker [Member] | Medical [Member] | Customer Concentration Risk [Member]	'	'
Medical segment	'	'
Stryker (in Dollars)	478	1,144
Medical [Member]	'	'
Medical segment	'	'
Stryker (in Dollars)	$3,060	$3,029

Note_2_Basic_and_Diluted_Net_L2

Note 2 - Basic and Diluted Net Loss per Common Share (Details) - Antidilutive Securities	3 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Antidilutive Securities	28,963,786	23,868,839
Convertible Debt Securities [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Antidilutive Securities	21,500,150	15,833,333
Equity Option [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Antidilutive Securities	4,346,369	6,076,858
Warrant [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Antidilutive Securities	1,880,620	1,880,620
Restricted Stock [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Antidilutive Securities	1,236,647	78,028

Note_3_Inventories_Details_Inv

Note 3 - Inventories (Details) - Inventories (USD $)	Jun. 30, 2014	Mar. 31, 2014
In Thousands, unless otherwise specified
Inventories [Abstract]	'	'
Raw materials	$3,482	$3,456
Work in process	318	329
Finished goods	392	409
Inventories, net	$4,192	$4,194

Note_5_Convetible_Debt_Related2

Note 5 - Convetible Debt - Related Party (Details) (USD $)

Jun. 30, 2014

Mar. 31, 2014

Mar. 13, 2014

Jan. 21, 2014

Nov. 26, 2013

Oct. 07, 2013

Jun. 30, 2014

Aug. 13, 2014

Sep. 30, 2011

Jun. 30, 2014

Sep. 25, 2013

Jun. 30, 2014

Jun. 30, 2014

Sep. 19, 2012

Jul. 25, 2012

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Board of Directors Chairman [Member]

Board of Directors Chairman [Member]

Board of Directors Chairman [Member]

The 2013 Note [Member]

The 2013 Note [Member]

The 2013 Note [Member]

Replacement Note [Member]

Replacement Note [Member]

Replacement Note [Member]

The Original Agreement [Member]

The Original Agreement [Member]

Convertible Debt [Member]

The 2014 Note [Member]

The 2014 Note [Member]

Replacement Note [Member]

Convertible Debt [Member]

Board of Directors Chairman [Member]

Note 5 - Convetible Debt - Related Party (Details) [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Long Term Debt Maximum Amount Lender Agreed To Provide Financial Assistance

'

'

'

'

'

'

$5,000,000

'

'

'

'

'

'

'

'

'

'

'

Related Party Transaction, Rate

'

'

'

'

'

'

1.91%

'

'

'

1.66%

'

0.84%

'

'

'

'

'

Debt Instrument, Convertible, Conversion Price (in Dollars per share)

'

'

$1.54

$1.39

$1.01

$0.95

$1.11

'

'

'

$0.89

'

$1.20

'

'

'

'

'

Convertible Debt, Noncurrent

23,440,000

22,414,000

'

'

'

'

1,000,000

2,000,000

15,000,000

'

'

'

'

20,000,000

'

'

'

'

Notes Payable, Related Parties

'

'

'

'

'

'

'

'

'

'

3,500,000

'

'

'

'

'

'

'

Convertible Debt

3,500,000

'

500,000

1,000,000

1,000,000

1,000,000

'

'

'

'

'

3,500,000

'

'

'

'

'

'

Debt Instrument, Unamortized Discount

'

'

'

'

'

'

'

'

'

1,060,000

'

'

'

'

'

'

'

-1,060,000

Debt Instrument, Convertible, Remaining Discount Amortization Period

'

'

'

'

'

'

'

'

'

'4 years 73 days

'

'

'

'

'

'

'

'

Notes Payable, Related Parties, Additional Borrowings Increase (Decrease)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5,000,000

'

'

'

Due to Related Parties

'

'

'

'

'

'

'

'

'

'

'

'

20,000,000

'

'

'

'

'

Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,880,620

'

'

Fair Value Assumptions, Exercise Price (in Dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$1.86

'

Accrued Liabilities, Current

$921,000

$918,000

'

'

'

'

'

'

'

'

'

'

$311,000

'

'

'

'

'

Note_5_Convetible_Debt_Related3

Note 5 - Convetible Debt - Related Party (Details) - Convertible Debt-Related Party (USD $)

Jun. 30, 2014

Mar. 31, 2014

Jun. 30, 2014

Jun. 30, 2014

Sep. 19, 2012

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

In Thousands, unless otherwise specified

Replacement Note [Member]

Replacement Note [Member]

Replacement Note [Member]

The 2013 Note [Member]

The 2013 Note [Member]

The 2013 Note [Member]

The 2014 Note [Member]

The 2014 Note [Member]

Gross Amount [Member]

Convertible Debt [Member]

Net Amount [Member]

Gross Amount [Member]

Net Amount [Member]

Gross Amount [Member]

Convertible Debt [Member]

Net Amount [Member]

Gross Amount [Member]

Net Amount [Member]

Related Party Transaction [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

Gross Principal Amount Outstanding

$23,440

$22,414

$20,000

$20,000

$20,000

$3,500

'

$2,440

$1,000

$1,000

$24,500

'

$23,440

Unamortized Debt Discount

'

'

'

'

'

'

-1,060

'

'

'

'

1,060

'

Net Amount Outstanding

$23,440

$22,414

$20,000

$20,000

$20,000

$3,500

'

$2,440

$1,000

$1,000

$24,500

'

$23,440

Note_5_Convetible_Debt_Related4

Note 5 - Convetible Debt - Related Party (Details) - Beneficial Conversion Feature Amounts (USD $)	0 Months Ended				15 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 13, 2014	Jan. 21, 2014	Nov. 26, 2013	Oct. 07, 2013	Jun. 30, 2014	Mar. 13, 2014	Jan. 21, 2014	Nov. 26, 2013	Oct. 07, 2013
Beneficial Conversion Feature Amounts [Abstract]	'	'	'	'	'	'	'	'	'
Borrowing Amount	'	'	'	'	$3,500	$500	$1,000	$1,000	$1,000
Convertible Shares	561,799	1,123,595	1,123,595	1,123,595	3,932,584	'	'	'	'
Share Price (in Dollars per share)	'	'	'	'	'	$1.54	$1.39	$1.01	$0.95
Gross Beneficial Conversion Feature	$365	$562	$135	$67	$1,129	'	'	'	'

Note_5_Convetible_Debt_Related5

Note 5 - Convetible Debt - Related Party (Details) - Debt Cost Expense and Interest Expense Related to Outstanding Borrowings (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013
Note 5 - Convetible Debt - Related Party (Details) - Debt Cost Expense and Interest Expense Related to Outstanding Borrowings [Line Items]	'	'
Amortization of convertible debt discount	($26)	'
	-83	-41
Related Party [Member]	'	'
Note 5 - Convetible Debt - Related Party (Details) - Debt Cost Expense and Interest Expense Related to Outstanding Borrowings [Line Items]	'	'
Interest Expense	($57)	($41)

Note_6_StockBased_Awards_Detai

Note 6 - Stock-Based Awards (Details) (USD $)	3 Months Ended						0 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2014	Jun. 30, 2014	Jun. 30, 2014	Aug. 15, 2003	Jun. 30, 2014
			Employee Stock Option [Member]	Restricted Stock [Member]	2000 Stock Incentive Plan [Member]	2007 Stock Incentive Plan [Member]	2003 Director Option Plan [Member]	2003 Director Option Plan [Member]
Note 6 - Stock-Based Awards (Details) [Line Items]	'	'	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	'	'	'	'	4,500,000	7,000,000	'	450,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures	'	'	'	'	'	'	10,000	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	'	'	'	'	'	'	10,000	'
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent	100.00%	'	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period	'10 years	'	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period	'4 years	'	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value	$0.77	$0.70	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value	$234,000	'	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value	180,000	'	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value	230,000	'	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate	0.00%	'	'	'	'	'	'	'
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options	600,000	'	'	'	'	'	'	'
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	'	'	'3 years 36 days	'3 years 146 days	'	'	'	'
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options	'	'	'	$400,000	'	'	'	'

Note_6_StockBased_Awards_Detai1

Note 6 - Stock-Based Awards (Details) - Stock Options Activity (USD $)	3 Months Ended
	Jun. 30, 2014	Mar. 31, 2014
Note 6 - Stock-Based Awards (Details) - Stock Options Activity [Line Items]	'	'
Outstanding, Number of Shares (in Shares)	4,356,369	4,377,874
Outstanding, Minimum Exercise Price Range	$0.85	$0.85
Outstanding, Maximum Exercise Price Range	$4.88	$4.88
Outstanding, Weighted Average Exercise Price	$1.64	$1.78
Outstanding, Weighted Average Remaining Contractual Life	'5 years 292 days	'6 years
Vested and expected to vest at June 30, 2014	$0.85	$0.85
Vested and expected to vest at June 30, 2014	$4.88	$4.88
Exercisable at June 30, 2014	$0.85	$0.85
Exercisable at June 30, 2014	$4.88	$4.88
Granted	$0.85	$0.85
Granted	$4.88	$4.88
Exercised	$0.85	$0.85
Exercised	$4.88	$4.88
Granted [Member]	'	'
Note 6 - Stock-Based Awards (Details) - Stock Options Activity [Line Items]	'	'
Outstanding, Minimum Exercise Price Range	$1.04	'
Outstanding, Maximum Exercise Price Range	$1.25	'
Vested and expected to vest at June 30, 2014	$1.04	'
Vested and expected to vest at June 30, 2014	$1.25	'
Exercisable at June 30, 2014	$1.04	'
Exercisable at June 30, 2014	$1.25	'
Granted (in Shares)	430,000	'
Granted	$1.04	'
Granted	$1.25	'
Granted	$1.12	'
Exercised	$1.04	'
Exercised	$1.25	'
Exercised [Member]	'	'
Note 6 - Stock-Based Awards (Details) - Stock Options Activity [Line Items]	'	'
Outstanding, Minimum Exercise Price Range	$0.97	'
Outstanding, Maximum Exercise Price Range	$0.97	'
Vested and expected to vest at June 30, 2014	$0.97	'
Vested and expected to vest at June 30, 2014	$0.97	'
Exercisable at June 30, 2014	$0.97	'
Exercisable at June 30, 2014	$0.97	'
Granted	$0.97	'
Granted	$0.97	'
Exercised (in Shares)	-25,000	'
Exercised	$0.97	'
Exercised	$0.97	'
Exercised	$0.97	'
Canceled [Member]	'	'
Note 6 - Stock-Based Awards (Details) - Stock Options Activity [Line Items]	'	'
Canceled (in Shares)	-426,505	'
Canceled	$0.95	'
Canceled	$4.30	'
Canceled	$2.65	'
Vested and Expected to Vest [Member]	'	'
Note 6 - Stock-Based Awards (Details) - Stock Options Activity [Line Items]	'	'
Outstanding, Minimum Exercise Price Range	$0.85	'
Outstanding, Maximum Exercise Price Range	$4.88	'
Vested and expected to vest at June 30, 2014 (in Shares)	4,310,973	'
Vested and expected to vest at June 30, 2014	$0.85	'
Vested and expected to vest at June 30, 2014	$4.88	'
Vested and expected to vest at June 30, 2014	$1.64	'
Vested and expected to vest at June 30, 2014	'5 years 292 days	'
Exercisable at June 30, 2014	$0.85	'
Exercisable at June 30, 2014	$4.88	'
Granted	$0.85	'
Granted	$4.88	'
Exercised	$0.85	'
Exercised	$4.88	'
Exercisable [Member]	'	'
Note 6 - Stock-Based Awards (Details) - Stock Options Activity [Line Items]	'	'
Outstanding, Minimum Exercise Price Range	$0.85	'
Outstanding, Maximum Exercise Price Range	$4.88	'
Vested and expected to vest at June 30, 2014	$0.85	'
Vested and expected to vest at June 30, 2014	$4.88	'
Exercisable at June 30, 2014 (in Shares)	3,558,703	'
Exercisable at June 30, 2014	$0.85	'
Exercisable at June 30, 2014	$4.88	'
Exercisable at June 30, 2014	$1.73	'
Exercisable at June 30, 2014	'5 years	'
Granted	$0.85	'
Granted	$4.88	'
Exercised	$0.85	'
Exercised	$4.88	'

Note_6_StockBased_Awards_Detai2

Note 6 - Stock-Based Awards (Details) - Restricted Stock Activity (Restricted Stock [Member], USD $)	3 Months Ended
	Jun. 30, 2014
Restricted Stock [Member]	'
Note 6 - Stock-Based Awards (Details) - Restricted Stock Activity [Line Items]	'
Nonvested - Number of Shares	1,325,402
Nonvested - Weighted Average Grant Price	$1.06
Vested	-68,950
Vested	$1.51
Forfeited	-19,805
Forfeited	$1.62
Nonvested - Number of Shares	1,236,647
Nonvested - Weighted Average Grant Price	$1.05

Note_6_StockBased_Awards_Detai3

Note 6 - Stock-Based Awards (Details) - Black-Scholes Valuation Assumptions	3 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Black-Scholes Valuation Assumptions [Abstract]	'	'
Risk-free interest rate	1.90%	1.30%
Expected life (in years)	'6 years 255 days	'7 years
Expected volatility	77.00%	82.00%

Note_6_StockBased_Awards_Detai4

Note 6 - Stock-Based Awards (Details) - Stock-based Compensation Expense (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]	'	'
Allocated stock-based compensation expense	$154	$555
Cost of Sales [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]	'	'
Allocated stock-based compensation expense	16	30
General and Administrative Expense [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]	'	'
Allocated stock-based compensation expense	123	509
Research and Development Expense [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]	'	'
Allocated stock-based compensation expense	$15	$16

Note_7_Treasury_Stock_Details_

Note 7 - Treasury Stock (Details) - Treasury Stock Activity (USD $)	3 Months Ended
In Thousands, except Share data, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013
Treasury Stock Activity [Abstract]	'	'
Number of Shares Repurchased	5	15
Cost	$6	$18
Weighted Average Purchase Price	$1.22	$1.14

Note_8_Segment_Information_Det

Note 8 - Segment Information (Details)	3 Months Ended
	Jun. 30, 2014
Segment Reporting [Abstract]	'
Number of Reportable Segments	2

Note_8_Segment_Information_Det1

Note 8 - Segment Information (Details) - Key Financial Highlights by Reportable Segments (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014		Jun. 30, 2013		Mar. 31, 2014
Segment Reporting Information [Line Items]	'		'		'
Net sales	$3,752		$3,652		'
Gross profit	1,149		1,080		'
Operating loss	-1,878		-2,389		'
Interest expense, net	83		41		'
Depreciation and amortization	166		188		'
Stock-based compensation expense	154		555		'
Total assets	10,378		11,070		10,833
Expenditures for fixed assets	25		'		'
Medical [Member]	'		'		'
Segment Reporting Information [Line Items]	'		'		'
Net sales	3,060		3,029		'
Gross profit	897		793		'
Operating loss	-1,838		-2,387		'
Interest expense, net	83		41		'
Depreciation and amortization	164		184		'
Stock-based compensation expense	142		531		'
Total assets	10,868		11,615		'
Expenditures for fixed assets	25		'		'
Industrial [Member]	'		'		'
Segment Reporting Information [Line Items]	'		'		'
Net sales	692		623		'
Gross profit	252		287		'
Operating loss	-40		-2		'
Depreciation and amortization	2		4		'
Stock-based compensation expense	12		24		'
Total assets	1,640		1,679		'
Adjustments [Member]	'		'		'
Segment Reporting Information [Line Items]	'		'		'
Total assets	($2,130)	[1]	($2,224)	[1]	'
[1]	Adjustments

Note_8_Segment_Information_Det2

Note 8 - Segment Information (Details) - Reportable Segment Adjustments (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013
Reportable Segment Adjustments [Abstract]	'	'
Intercompany eliminations	($1,444)	($1,538)
Investment in subsidiaries	-686	-686
Total adjustments	($2,130)	($2,224)

Note_9_Subsequent_Event_Detail

Note 9 - Subsequent Event (Details) (USD $)	3 Months Ended			0 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Mar. 31, 2014	Aug. 13, 2014	Jun. 30, 2014
				Board of Directors Chairman [Member]	Board of Directors Chairman [Member]
				The 2014 Note [Member]	The 2014 Note [Member]
Note 9 - Subsequent Event (Details) [Line Items]	'	'	'	'	'
Proceeds from Convertible Debt	$1,000	$2,000	'	$1,000	'
Convertible Debt, Noncurrent	$23,440	'	$22,414	$2,000	$1,000